The benefit held up regardless of which radiation therapy approach doctors used
In the long human struggle against cancer, a small Massachusetts biotech has reached a quiet but consequential threshold: clinical evidence that a virus, repurposed as a messenger, can teach the immune system to recognize and destroy what it once ignored. Candel Therapeutics reported in November 2025 that its lead therapy extended disease-free survival in prostate cancer patients by more than a third, while early signals in one of the brain's most lethal tumors suggest some patients are living years beyond what the disease typically allows. Backed by $130 million in new financing, the company now faces the harder work of proving these results hold across larger populations and different cancers — a journey measured not in quarters, but in the lives of patients who have no other road.
- A modified virus injected directly into tumors is showing it can trigger the immune system to fight cancer systemically — a 38% improvement in disease-free survival in prostate cancer is the clearest proof yet.
- Patients with recurrent glioblastoma, a cancer that rarely grants more than months, are among those generating the most urgent questions — four of nine treated patients remained alive at data cutoff, some beyond a year.
- The company's cash burn is accelerating as it races to prepare a regulatory filing, launch a lung cancer trial, and sustain three simultaneous clinical programs, creating real financial pressure beneath the optimism.
- A $130 million debt facility buys time — runway into early 2027 — but the clock is tied to hitting regulatory and clinical milestones that are not yet guaranteed.
- The addition of CAR-T pioneer Carl June to the scientific advisory board signals that Candel is positioning itself for credibility as much as capital, aware that the next phase requires institutional trust as well as data.
Candel Therapeutics, based in Massachusetts, reported third-quarter 2025 results in November alongside a series of clinical and financial milestones that suggest its experimental cancer immunotherapy pipeline is gaining traction on several fronts.
The most advanced program centers on CAN-2409, a therapy that injects a genetically modified virus directly into tumor tissue. When paired with an antiviral drug, the virus triggers cancer cell death and signals the immune system to attack tumors throughout the body. Data presented at a major radiation oncology conference showed the treatment improved prostate cancer-specific disease-free survival by 38 percent compared to placebo — a result that held regardless of which radiation approach patients received. The company is targeting a regulatory filing in the fourth quarter of 2026 and plans to launch a pivotal phase 3 trial in lung cancer patients in the second quarter of that year, focusing on those whose disease has progressed despite immunotherapy.
A second candidate, CAN-3110, is showing early promise in recurrent glioblastoma — one of oncology's most resistant diseases. In a phase 1b trial, four of nine patients who received multiple injections were still alive at the data cutoff, with some surpassing a year of survival. A paper in Science Translational Medicine revealed that serial tumor biopsies from two patients showed immune activity that conventional imaging had failed to detect, suggesting the drug may be working at a cellular level even when scans appear unchanged.
To sustain this work, Candel secured a $130 million term loan from Trinity Capital in October, drawing $50 million immediately with access to more upon hitting defined milestones. Combined with existing cash, the company projects it can fund operations into early 2027 — though quarterly research and development spending has risen sharply, reaching $8.5 million in Q3 2025 compared to $5.4 million a year prior.
Candel also welcomed two prominent scientists to its advisory board and made the strategic decision to pause its pancreatic cancer program, concentrating resources on the two indications where its evidence is strongest. The road ahead is long — the lung cancer trial alone will take years — but the company is betting that its prostate cancer data is compelling enough to open a regulatory door, and that the patterns emerging in glioma point toward something worth pursuing.
Candel Therapeutics, a Massachusetts-based biotech company, is moving three experimental cancer treatments through clinical trials with a mix of encouraging results and fresh financial backing. On November 13, the company reported third-quarter earnings and announced a series of milestones that suggest its pipeline is advancing on multiple fronts.
The headline news centers on CAN-2409, an investigational immunotherapy designed to fight solid tumors by injecting a modified virus directly into cancer tissue. The virus carries genetic instructions that, when combined with an antiviral drug, triggers tumor cell death and alerts the immune system to attack cancer cells throughout the body. At the American Society for Radiation Oncology's annual meeting, Candel presented new data from its completed phase 3 trial in prostate cancer. The study showed that CAN-2409 improved disease-free survival by 38 percent compared to placebo, and this benefit held up regardless of which radiation therapy approach doctors used—whether conventional treatment over weeks or a faster hypofractionated schedule. The company plans to file for regulatory approval in the fourth quarter of 2026.
Building on that momentum, Candel is preparing to launch a larger, pivotal phase 3 trial of CAN-2409 in lung cancer patients whose disease has worsened despite immune checkpoint inhibitor therapy, a common problem in oncology. That trial is expected to begin in the second quarter of 2026. The company also reported encouraging survival data from a smaller phase 1b trial of a second candidate, CAN-3110, in patients with recurrent high-grade glioblastoma. Four of nine patients who received multiple injections were still alive at the time of the data cutoff, with some surviving more than a year after treatment began. A scientific paper published in Science Translational Medicine detailed how serial tumor biopsies from two of those patients revealed immune responses that standard clinical measures had missed, suggesting the drug was working at a cellular level even when conventional imaging looked unchanged.
To fund these ambitions, Candel secured a $130 million term loan facility from Trinity Capital in October. The company drew down $50 million at closing and has access to up to $80 million more if it hits certain regulatory and clinical milestones. Combined with $87 million in cash on hand as of September 30, the company says it has runway to fund operations into the first quarter of 2027. The debt comes as the company's quarterly cash burn has increased—research and development expenses were $8.5 million in the third quarter of 2025, up from $5.4 million a year earlier, driven by manufacturing, regulatory work, and hiring.
Candel also made two notable additions to its scientific advisory board: Carl June, a pioneer of CAR-T cell therapy, and Bali Pulendran, an expert in systems immunology. The company paused its pancreatic cancer program to focus resources on prostate cancer and lung cancer, though it left the door open to revive that work if external funding materializes.
The path ahead is crowded with data readouts. Extended follow-up results from the prostate cancer trial are due in the second quarter of 2026. Mature survival data from the glioma trial is expected in the fourth quarter of 2026. The lung cancer trial, if it launches on schedule, will take years to complete. For now, Candel is betting that the prostate cancer data is strong enough to support a regulatory filing, and that the lung cancer trial will prove the approach works in a disease where options are limited.
Notable Quotes
We continue to work toward a planned BLA submission in Q4 2026. We presented additional supportive data from our positive phase 3 trial of CAN-2409 in newly diagnosed, localized prostate cancer during an oral presentation at the Association of Radiation Oncology Annual Meeting.— Paul Peter Tak, M.D., Ph.D., President and CEO of Candel Therapeutics
We were pleased to secure strategic, non-dilutive funding through a five-year, $130 million term loan facility with Trinity Capital, Inc., which strengthens our balance sheet and positions us to advance our key priorities, including the initiation of a pivotal phase 3 clinical trial of CAN-2409 in NSCLC.— Paul Peter Tak, M.D., Ph.D., President and CEO of Candel Therapeutics
The Hearth Conversation Another angle on the story
What makes this company's approach different from other cancer immunotherapies already on the market?
They're using a virus as a delivery vehicle—specifically, a modified adenovirus that carries a gene into the tumor. Once inside, that gene converts a prodrug into something that kills cancer cells and triggers the immune system. It's not a checkpoint inhibitor, which is what most lung cancer patients have already tried. It's an in situ vaccination, essentially.
And the prostate cancer data—what does a 38 percent improvement in disease-free survival actually mean for patients?
It means fewer men had their cancer come back or spread during the follow-up period. But the real question is whether that translates to living longer overall. They're still collecting that data. What's notable is that the benefit held up whether men got conventional radiation or the faster schedule, which suggests the drug works across different treatment contexts.
Why is lung cancer the next big bet?
Because it's a huge unmet need. These are patients whose tumors have already resisted checkpoint inhibitors—the standard first-line treatment. There aren't many good options left. If CAN-2409 works there, the market is enormous.
The glioma data mentions patients surviving more than five years. That's remarkable for glioblastoma.
It is. But it's a tiny sample—nine patients total, and only four alive at the cutoff. The paper in Science Translational Medicine is interesting because it shows immune activity in the tumor that you wouldn't see on an MRI. That suggests something is happening, even if we don't fully understand it yet.
What's the financial risk here?
They're burning through cash faster as trials expand. The debt facility buys them time, but they're betting on hitting regulatory milestones to unlock more funding. If the lung cancer trial disappoints, or if the prostate cancer BLA gets delayed, they could run into trouble.